Feb 22, 2021
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
Feb 18, 2021
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
Feb 17, 2021
Mind Cure Comments on Recent Promotional Activity
Feb 17, 2021
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Feb 16, 2021
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
Jan 21, 2021
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
Jan 12, 2021
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
Jan 06, 2021
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
Dec 31, 2020
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
Dec 29, 2020
Mind Cure Announces Novel Supplement Product to Address Teen Wellness
Dec 10, 2020
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
Dec 08, 2020
Mind Cure Announces its Research Program with Psychedelic Compounds
Dec 02, 2020
Mind Cure Announces Eligibility for DTC Trading
Dec 01, 2020
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
Nov 10, 2020
Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer